Nabors Industries (NBR) Gets Double Upgrade from Analyst
The share price of Nabors Industries Ltd.
Insider Monkey Blog
Here is Why Diversified Energy (DEC) Gained This Week
The share price of Diversified Energy Company (NYSE:DEC) surged by 2.93% between December 22 and December 29, 2025, putting it among the Energy Stocks that Gained the Most This...
Kolibri Global Energy (KGEI) Provides Operational Update on Oklahoma Field
The share price of Kolibri Global Energy Inc.
Sable Offshore (SOC) – Among the Energy Stocks that Gained This Week
The share price of Sable Offshore Corp.
Morgan Stanley Analyst Assigns Hold Rating to Truist Financial (TFC)
Truist Financial Corporation (NYSE:TFC) is one of the new stocks David Tepper has bought.
10 Best Long-Term Investments for Kids
By late 2025, long-term investing for children has evolved from simple college savings into a full “cradle-to-retirement” wealth-building ecosystem.
9 Best Auto Stocks to Buy Now
According to figures issued by the European Automobile Manufacturers' Association (ACEA) on December 23, European new car sales increased year over year in November for the fifth...
Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB)
On December 15, TheFly published that Luke Sergott, a Barclays analyst, lifted the price objective for Pacific Biosciences of California, Inc.
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)
On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price objective of $11 instead of $10.
Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP)
TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74.
Barclays Keeps Its Overweight Rating On Twist Bioscience Corporation (TWST)
TheFly reported on December 15, 2025, that Barclays kept its Overweight rating and boosted its price objective for Twist Bioscience Corporation (NASDAQ:TWST) from $37 to $39.
Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)
The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40.
Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM)
TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95.
What Do Analysts Think About GeneDx Holdings Corp. (WGS)?
TheFly reported that on December 22, 2025, GeneDx Holdings Corp. (NASDAQ:WGS) lifted its price objective at Canaccord from $160 to $170.
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE)
TheFly reports that on December 19, 2025, H.C. Wainwright upgraded Wave Life Sciences Ltd. (NASDAQ:WVE)’s price target from $22 to $30.
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene
TheFly reported on December 2, 2025, that Beam Therapeutics Inc.
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data
Prime Medicine, Inc.
20 Best Performing Dividend Stocks in 2025
2025 has felt like another strong year for stocks. The S&P 500 is up close to 18% so far.
10 Big Names Crumbling Before 2026
ASP Isotopes extended its losing streak to a third day on Tuesday, shedding 5.08 percent to close at $5.42 apiece as investors mirrored a key executive’s disposition of a significant...
10 Stocks on Fire Ahead of 2026
Meanwhile, Wall Street’s major indices all finished in the red, with the Nasdaq leading the drop by 0.24 percent, followed by the Dow Jones, down 0.20 percent, and the S&P 500...
BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View
On December 15, Bank of America raised its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $700 from $650 and kept a Buy rating on the shares.
Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market
Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market.
Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar
On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis.
BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View
On December 15, BofA lowered the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $233 from $248 and kept a Neutral rating.
FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential
On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc.
Pfizer (PFE) Braces for Bumpy Years as Growth Pushed Out to 2029
On December 16, Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy, starting in 2026.
CVS Gets Higher Target as Bernstein Cites Management Confidence
On December 12, Bernstein raised the firm’s price target on CVS Health Corporation (NYSE:CVS) to $87 from $86 and kept a Market Perform rating after what it described as a very...
Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating
Bristol-Myers Squibb Company (NYSE:BMY) presents a measured balance between risk and reward. The stock offers a 4.6% dividend yield, and the payout ratio sits near 85%.
McKesson (MCK) Gets Higher Target at Deutsche Bank Despite Planned Spin-Off
On December 10, Deutsche Bank analyst George Hill raised the firm’s price target on McKesson Corporation (NYSE:MCK) to $904 from $861 and kept a Buy rating on the shares.
BofA Downgrades Zoetis (ZTS) to Neutral, Cuts Price Target
In other news, on December 5, Zoetis Inc.
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment
On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation...
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs
On December 19, Gilead Sciences, Inc. (NASDAQ:GILD) announced an agreement with the US government aimed at lowering drug costs for Americans.
Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves
On December 9, Barclays analyst Glen Santangelo initiated coverage of Viatris Inc. (NASDAQ:VTRS) with an Overweight rating and a $15 price target.
Major Shareholder Increases Stake in Prairie Operating Co. (PROP)
The share price of Prairie Operating Co.
12 Unstoppable Technology Stocks to Buy
On December 30, Dan Greenhaus, Chief Strategist and Managing Director at Solus Alternative Asset Management, appeared on a CNBC Television interview to discuss the themes driving...
7 Affordable Stocks With Good Earnings Growth for 2026
On December 29, Jeremy Siegel, professor emeritus of finance at the University of Pennsylvania and chief economist at WisdomTree, appeared on CNBC's “Squawk Box” to talk about...
10 Best Low Priced Technology Stocks to Buy According to Analysts
On December 24, Ben Emons, Founder at FedWatch Advisors, joined CNBC to suggest that markets are setting up for a Santa rally, favoring tech, consumer discretionary, bitcoin, ...
S&P Global (SPGI) Partners with Google Cloud to Accelerate AI Transformation
On December 10, S&P Global Inc. (NYSE:SPGI) announced a multi-year strategic partnership with Google Cloud.
BofA Raises Coca-Cola (KO) Target as 2026 Consumption Growth Remains Unclear
On December 19, BofA analyst Peter Galbo raised the price target on The Coca-Cola Company (NYSE:KO) to $85 from $80 and kept a Buy rating.
Bernstein Raises Caterpillar (CAT) Target as 2026 Recovery Comes Into View
On December 19, Bernstein raised its price target on Caterpillar Inc. (NYSE:CAT) to $630 from $557 and kept a Market Perform rating.
Ecolab (ECL) Target Trimmed at Citi Amid Shifting Views on Chemicals
On December 18, Citi analyst Patrick Cunningham lowered the price target on Ecolab Inc. (NYSE:ECL) to $315 from $323 and maintained a Buy rating.
ADP Downgraded to Underperform as Jefferies Flags Structural Headwinds
On December 16, Jefferies analyst Samad Samana downgraded Automatic Data Processing, Inc. (NASDAQ:ADP) to Underperform from Hold and cut the price target to $230 from $245.
11 Best NYSE Stocks Under $5 to Buy
Investors often refer to stocks trading below $5 per share as small capitalization stocks.
Colgate-Palmolive (CL) Target Raised as Analysts Split on 2026 Staples Outlook
On December 19, BofA raised its price target on Colgate-Palmolive Company (NYSE:CL) to $90 from $88 and kept a Buy rating.
Dover (DOV) Price Target Lifted as BofA Sees Momentum Carrying Into 2026
On December 15, BofA analyst Andrew Obin raised the price target on Dover Corporation (NYSE:DOV) to $240 from $225 and maintained a Buy rating.
Mixed Analyst Moves on Air Products (APD) Highlight Ongoing Sector Headwinds
On December 19, Wells Fargo analyst Michael Sison downgraded Air Products and Chemicals, Inc.
Citi Upgrades Church & Dwight (CHD) to Neutral as Sales Outlook Improves
On December 17, Citi moved Church & Dwight Co., Inc. (NYSE:CHD) to Neutral from Sell and raised its price target to $87 from $85.
Kimberly-Clark (KMB) Target Lowered as Citi Rebalances Household Care View
On December 17, Citi lowered its price target on Kimberly-Clark Corporation (NASDAQ:KMB) to $95 from $100 and kept a Sell rating on the stock.
Hedge Fund Resource Center
